AU2001261987A1 - Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders - Google Patents

Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders

Info

Publication number
AU2001261987A1
AU2001261987A1 AU2001261987A AU6198701A AU2001261987A1 AU 2001261987 A1 AU2001261987 A1 AU 2001261987A1 AU 2001261987 A AU2001261987 A AU 2001261987A AU 6198701 A AU6198701 A AU 6198701A AU 2001261987 A1 AU2001261987 A1 AU 2001261987A1
Authority
AU
Australia
Prior art keywords
treatment
neurodegenerative
patient
apoptotic
neurological disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261987A
Other languages
English (en)
Inventor
Anthony E. Bolton
Arkady Mandel
Daniel Sauder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of AU2001261987A1 publication Critical patent/AU2001261987A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001261987A 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders Abandoned AU2001261987A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA 2309424 CA2309424A1 (en) 2000-05-25 2000-05-25 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2,309,424 2000-05-25
PCT/CA2001/000759 WO2001089537A2 (en) 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders

Publications (1)

Publication Number Publication Date
AU2001261987A1 true AU2001261987A1 (en) 2001-12-03

Family

ID=4166243

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261987A Abandoned AU2001261987A1 (en) 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders

Country Status (13)

Country Link
US (3) US7132285B2 (de)
EP (1) EP1289535B1 (de)
JP (1) JP2003534282A (de)
AT (1) ATE366581T1 (de)
AU (1) AU2001261987A1 (de)
CA (1) CA2309424A1 (de)
DE (1) DE60129322T2 (de)
DK (1) DK1289535T3 (de)
ES (1) ES2290134T3 (de)
HK (1) HK1055080A1 (de)
PT (1) PT1289535E (de)
TW (1) TWI239843B (de)
WO (1) WO2001089537A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309518A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
TWI281407B (en) * 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
CA2333494A1 (en) * 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
WO2003024423A1 (en) * 2001-09-18 2003-03-27 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20060008517A1 (en) * 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
EP3865139B1 (de) 2015-02-18 2023-05-03 Enlivex Therapeutics Rdo Ltd Kombinationsimmuntherapie und cytokinkontrolltherapie zur krebsbehandlung
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) * 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
AU2016250570B2 (en) 2015-04-21 2021-07-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6696092B2 (en) * 1992-02-07 2004-02-24 Vasogen Ireland Limited Endothelial lining effects and treatment of vasospastic disorders
ES2179828T3 (es) 1992-02-07 2003-02-01 Vasogen Ireland Ltd Procedimiento para incrementar la concentracion de oxido nitrico en la sangre.
CA2360268A1 (en) 1999-01-12 2000-07-20 Vasogen Ireland Limited Pre-conditioning against cell death
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
ES2202165T3 (es) 2000-03-07 2004-04-01 E.F.P. Floor Products Fussboden Gmbh Panel, especialmente panel para suelo.
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2309518A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
US7122208B2 (en) * 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities
US20030157073A1 (en) 2001-11-29 2003-08-21 Peritt David L. Methods for pretreating a subject with apoptotic cells
US7255880B2 (en) * 2003-04-03 2007-08-14 Vasogen Ireland Limited Treatment of endothelin-related disorders

Also Published As

Publication number Publication date
US20020044924A1 (en) 2002-04-18
ES2290134T3 (es) 2008-02-16
EP1289535A2 (de) 2003-03-12
ATE366581T1 (de) 2007-08-15
DE60129322T2 (de) 2008-03-13
EP1289535B1 (de) 2007-07-11
HK1055080A1 (en) 2003-12-24
CA2309424A1 (en) 2001-11-25
WO2001089537A2 (en) 2001-11-29
US7132285B2 (en) 2006-11-07
PT1289535E (pt) 2007-10-19
TWI239843B (en) 2005-09-21
US20070087010A1 (en) 2007-04-19
WO2001089537A3 (en) 2002-08-01
DK1289535T3 (da) 2007-11-05
JP2003534282A (ja) 2003-11-18
DE60129322D1 (de) 2007-08-23
US20080131416A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
PL307339A1 (en) Terephandin metabolites and their optically pure isomers for treating allergic disorders
UA29505C2 (uk) Фармацевтична композиція для лікування і/або профілактики розрідження кістки і спосіб лікування і/або профілактики розрідження кістки у ссавців
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
HUT63564A (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
IL139230A0 (en) Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds to the upper respiratory tract and/or the ear
AU2001261987A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
PT2111868E (pt) Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos
GB2285219B (en) Use of norastemizole for the treatment of allergic disorders
BR0307041A (pt) Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes
GB9023701D0 (en) Medical treatment
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
IL163091A (en) Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction
WO2001089538A3 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
DE69921678D1 (de) Zusammensetzung enthaltend di- und trinatriumsalze von echinochrome zur behandlung von augenerkrankungen
RU94000695A (ru) Средство с противоаллергическим действием
GB9617611D0 (en) Treatment of autoimmune disease
UA31177A (uk) Спосіб лікування нейросенсорної приглухуватості
MX9503363A (es) N-(2,6-dioxo-3-piperidil) ftalimida (generico talidomida como tratamiento del sindrome de desgaste asociado con la infeccion por vih-1.
MD1505F1 (en) Preparation for treatment of rheumatoid affections
BG107546U (en) Balm for the restoration of skin impairments
RU94016144A (ru) Средство для лечения больных болезнью рейтера